A Study To Investigate Tanezumab In Patients With Interstitial Cystitis/ Painful Bladder Syndrome

Phase 2

Terminated

Conditions: Cystitis, Interstitial

Interventions: Biological: Tanezumab
Other: Placebo

Registration Number: NCT00999518

Lead Sponsor: Pfizer

Brief Summary: In a previous study in patients with interstitial cystitis/ painful bladder syndrome (IC/PBS), tanezumab has shown to be efficacious in relieving the pain associated with IC/PBS, as well as some effect on reducing urinary urgency. Only one dose was studied, and tanezumab was well tolerated. In this study, the hypothesis being tested is that tanezumab will show efficacy at several doses on reducing pain with sufficient tolerability. Tanezumab's safety will also be assessed at different dose levels

Detailed Description: This study was terminated on 16 November 2010 following a US FDA partial clinical hold for the tanezumab interstitial cystitis clinical study announced on 19 July 2010 for potential safety issues, and following a pre-planned interim analysis.

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 205

Inclusion Criteria

Patients with interstitial cystitis/ painful bladder syndrome for more than 6 months with moderate to severe pain and a micturition frequency greater than 7 per day.
Patients who have been on stable oral medicines for interstitial cystitis/ painful bladder syndrome for at least 3 months. Other therapies might need to be stopped.

Exclusion Criteria

Patients on certain recent treatments for interstitial cystitis/ painful bladder syndrome.
Body mass index (BMI) of >39 kg/m2.
History of allergic or anaphylactic reaction to a therapeutic or diagnostic monoclonal antibody or IgG-fusion protein.
Patients with peripheral neuropathy.
Patients with Type I or type II diabetes mellitus who have an HbA1c > 8.0%.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Group 3	Tanezumab	-
Group 1	Tanezumab	-
Group 2	Tanezumab	-
Group 4	Tanezumab	-
Group 5	Placebo	-

Primary Outcome Measures

Name	Time	Method
Change From Baseline in Mean Average Daily Pain Score at Week 8	Baseline, Week 8	Average daily pain score was defined as the mean of the last 7 daily diary pain ratings prior to each assessment time point. Participants rated their average bladder pain due to interstitial cystitis/painful bladder syndrome (IC/PBS) over the past 24 hours on an 11-point numeric rating scale (NRS) ranging from 0 = no bladder pain to 10 = worst possible bladder pain.

Secondary Outcome Measures

Name	Time	Method
Change From Baseline in Mean Average Daily Pain Score at Week 1, 2, 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, and 24	Baseline, Week 1, 2, 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24	Average daily pain score was defined as the mean of the last 7 daily diary pain ratings prior to each assessment time point. Participants rated their average bladder pain due to interstitial cystitis/painful bladder syndrome (IC/PBS) over the past 24 hours on an 11-point numeric rating scale (NRS) ranging from 0 = no bladder pain to 10 = worst possible bladder pain.
Patient Global Assessment of Health Status Scores	Baseline, Week 2, 8, 16, 24	Participants answered: "Considering all the ways your bladder condition (IC/PBS) affects you, how are you doing today?" Participants responded on a 5-point scale where 1 = very good and 5 = very poor.
Participant's Urge to Urinate	Baseline, Week 4, 8, 12, 16, 20, 24	Participants completed 7-item questionnaire assessing their urge to urinate over the past 24 hours. The items were assessed on a 5-point response scale ranging from 0 (never) to 4 (always). Urge to urinate was calculated as the total of the 7 'urge' items with a minimum total score of 0 and a maximum total score of 28. Higher scores indicated greater symptom severity. An average was determined from the 3 days recorded in the 7-day diary period prior to each assessment time point.
Brief Pain Inventory-Short Form (BPI-sf) Score	Baseline, Week 8, 16, 24	BPI-sf is a 7-item self-administered questionnaire to assess the pain severity and pain interference on daily functions. Pain Severity Index (PSI) is an average of Questions 2-5 which measured the severity of pain (worst, least, average, right now) over past 24-hours on an 11-point scale (0=no pain to 10=pain as bad as you can imagine). Pain Interference Index (PII) is an average of 7 pain interference items of Question 7 that measured the level of interference of pain on daily function (general activity, mood, walking ability, normal work, relations with other people, sleep, enjoyment of life) on an 11-point scale (0=did not interfere to 10=completely interfered). Pain Severity Index and Pain Interference Index total scores ranged from 0 to 10, where higher scores indicate greater pain or greater interference.
Percentage of Participants Who Achieved At Least 30 Percent (%) and 50% Reduction in Mean Average Daily Pain Score	Week 8, 16	Average daily pain score was defined as the mean of the last 7 daily diary pain ratings prior to each assessment time point. Participants rated their average bladder pain due to interstitial cystitis/painful bladder syndrome (IC/PBS) over the past 24 hours on an 11-point numeric rating scale (NRS) ranging from 0 = no bladder pain to 10 = worst possible bladder pain.
Number of Nocturnal Micturitions Per 24 Hours	Baseline, Week 4, 8, 12, 16, 20, 24	The nocturnal frequency per 24 hours was defined as the number of voids after going to bed and before getting up (the times of going to bed and getting up were recorded in the diary). The nocturnal micturition per 24 hours was calculated as the sum of voluntary voids that occurred during a night's sleep, divided by the number of nights over which this was collected.
Number of Micturition-related Urgency Episodes Per 24 Hours	Baseline, Week 4, 8, 12, 16, 20, 24	The micturition urgency frequency per 24 hours was calculated as the sum of urgency episodes (when participant had to rush to get to the bathroom to urinate) occurring during the diary period when this was measured, divided by the number of days over which they were recorded.
Number of Participants With Patient Global Satisfaction Assessment Scores	Week 8, 16, 24	Participant global satisfaction is assessed using Patient Reported Treatment Impact (PRTI) which is a self-administered questionnaire containing 4 items to assess participant satisfaction, previous treatment, preference and willingness to continue using the study medication. Participants were asked: "Overall, how satisfied are you with the drug that you received since you entered this trial?" Participant's response is rated on a 5-point scale where 1=extremely dissatisfied (dissatisf), 2=dissatisfied, 3=neither satisfied nor dissatisfied (satisfy/dissatisfy), 4=satisfied and 5=extremely satisfied. Number of participants with each response is reported.
Painful Bladder/Interstitial Cystitis Quality of Life Questionnaire (PBIC-QoL) Total Score	Baseline, Week 2, 8, 16, 24	PBIC-QoL: 25-item questionnaire to assess impact of IC/PBS on health related quality of life over past 7 days. PBIC-QoL included 17 items (Items 2, 5, 8, 11, 14, 18, 20 and 21 did not form part of final instrument), of which 13 were divided into 3 dimensions: activity limitations (Items 1, 3, 4, 6, 7), impact on emotional wellbeing (Items 13, 15, 16, 17, 19), impact on sleep (Items 22, 23, 24). Four items: Item 9 (impact on going out with friends), Item 10 (impact on concentration), Item 12 (impact on eating and drinking), Item 25 (impact on sex life) were scored separately to dimension scores as single items. Items were scored from 4 'not at all' to 0 'extremely difficult' or 'a very great deal'. Eight items included a 'not applicable' response option. Dimension scores ranged from 0 to 4, higher score indicate better quality of life. Total score=sum of the dimension and single item scores, ranged from 0 to 28, higher score indicated better quality of life.
Amount of Rescue Medication Taken Per Week	Baseline, Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24	In case of inadequate pain relief or worsening symptoms of IC/PBS, acetaminophen up to 3000 mg per day (1500 mg/day for Japanese population) could be taken as rescue medication.
Number of Participants With Global Response Assessment Scores	Week 8, 16, 24	Participants were asked: "compared to when you began this trial, how would you rate your IC/PBS symptoms now?" Participants responded by using a 7-point symmetric scale where 1 = markedly worse, 2 = moderately worse, 3 = slightly worse, 4 = no change, 5 = slightly improved, 6 = moderately improved, and 7 = markedly improved.
Mean Voided Volume Per Micturition	Baseline, Week 4, 8, 12, 16, 20, 24	Mean volume voided per micturition was calculated as the total urine volume voided during the diary period when this was measured over 1 day, divided by the number of voids (with non missing volumes) during that day.
Number of Participants With Patient Global Preference Assessment Score	Week 8, 16, 24	Participant global preference is assessed using PRTI which is self-administered questionnaire containing 4 items to assess participant satisfaction, previous treatment (T/T), preference and willingness to continue using study medication. Participant reported previous T/T under following categories: lifestyle interventions, physical therapies, toileting programs, drug given into bladder, drug taken by mouth, surgery, and no T/T. Participant preference was assessed on a 5-point scale where, 1=No, I definitely prefer my prior T/T (Def Pref Prior), 2=I have a slight preference for my prior T/T (Slight Pref Prior T/T), 3=I have no preference either way (No preference), 4=I have a slight preference for the drug that I am receiving now (Slight Pref Current), 5=Yes, I definitely prefer the drug that I am receiving (Def Pref Current Drug) now. Number of participants under each of the categories is reported. For previous T/T, a single participant may be represented in more than 1 category.
Percentage of Participants Who Received Rescue Medication	Baseline, Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24	For inadequate pain relief or worsening symptoms of IC/PBS, participants took acetaminophen up to 3000 mg per day (1500 mg/day for Japanese population) as rescue medication.
O'Leary-Sant Interstitial Cystitis Symptom Index (ICSI) Score	Baseline, Week 2, 8, 16, 24	The ICSI contained 4 questions that measured symptom severity including urinary urgency, urinary frequency, nocturia and pain/burning in the bladder. Each question in the ICSI was rated on a 0-5 scale. The sum of the individual question ratings was the total score for the ICSI. Total scores ranged from 0 to 20, with higher scores indicating greater symptom severity and bother.
Number of Participants With Willingness to Re-use Medicine Assessment	Week 8, 16, 24	Participant willingness to re-use study medication is assessed using PRTI which is a self-administered questionnaire containing four items to assess participant satisfaction, previous treatment, preference and willingness to continue using the study medication. Participants were asked: "In the future, would you be willing to use the same drug that you have received since you entered this trial for your chronic prostatitis?" Participants responded on 5-point scale where, 1=No, I definitely would not want to use the same drug again (definitely not want), 2=I might not want to use the same drug again (might not want), 3=I am not sure (not sure), 4=I might want to use the same drug again (might want), 5=Yes, I would definitely want to use the same drug again (definitely want).
Serum Total Nerve Growth Factor (NGF) Levels	Baseline, Week 1, 2, 8, 16, 24	Serum samples were analyzed for total NGF using a validated, sensitive and specific immunoaffinity enrichment liquid chromatography tandem mass spectrometric method (IA/LC/MS/MS) method.
Change From Baseline in Mean Worst Daily Pain Score at Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24	Baseline, Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24	Worst daily pain score was defined as the mean of the last 7 daily diary pain ratings prior to each assessment time point. Participants rated their worst bladder pain due to IC/PBS over the past 24 hours on an 11-point NRS ranging from 0 = no bladder pain to 10 = worst possible bladder pain.
Number of Micturitions Per 24 Hours	Baseline, Week 4, 8, 12, 16, 20, 24	The micturition frequency per 24 hours was calculated from the sum of voids divided by the diary period over which they were collected.
Euro Quality of Life (EQ-5D) - Health State Profile Utility Score	Baseline, Week 8, 16, 24	EQ-5D is a participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.
Number of Days of Rescue Medication Usage Per Week	Baseline, Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24	In case of inadequate pain relief or worsening symptoms of IC/PBS, participants took acetaminophen up to 3000 mg per day (1500 mg/day for Japanese population) as rescue medication.
Number of Rescue Medication Doses Used Per Week	Baseline, Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24	In case of inadequate pain relief or worsening symptoms of IC/PBS, participants took acetaminophen up to 3000 mg per day (1500 mg/day for Japanese population) as rescue medication.

Trial Locations

Locations (169): Alpha Clinical Research
🇺🇸
Brighton, Massachusetts, United States
TriCities Medical Research
🇺🇸
Bristol, Tennessee, United States
Urology Associates / Urologic Medical Research
🇨🇦
Kitchener, Ontario, Canada
Anthony Skehan Medicine Professional Corporation
🇨🇦
Thunder Bay, Ontario, Canada
Columbus Urology Research, LLC
🇺🇸
Columbus, Ohio, United States
Marc Kirschner, MD
🇺🇸
Seattle, Washington, United States
Mobley Research Center
🇺🇸
Houston, Texas, United States
Centex Research, Inc.
🇺🇸
Houston, Texas, United States
Tri-State Urologic Services PSC, Inc. dba The Urology Group
🇺🇸
Cincinnati, Ohio, United States
Universitair Ziekenhuis Antwerpen
🇧🇪
Edegem, Belgium
Elite Clinical Studies, LLC
🇺🇸
Phoenix, Arizona, United States
Valley Urologic Associates
🇺🇸
Phoenix, Arizona, United States
Urology Specialists, Ltd.
🇺🇸
Phoenix, Arizona, United States
Central Arizona Urologists
🇺🇸
Phoenix, Arizona, United States
Precision Trials, LLC
🇺🇸
Phoenix, Arizona, United States
Valley Radiologists (x-ray only)
🇺🇸
Phoenix, Arizona, United States
Legacy Clinical Research, LLC
🇺🇸
Oklahoma City, Oklahoma, United States
The Center for Reproductive Health
🇺🇸
Nashville, Tennessee, United States
Access Clinical Trials, Inc (ACT)
🇺🇸
Nashville, Tennessee, United States
Swan and Brennan, Incorporated
🇺🇸
Nashville, Tennessee, United States
Center for Urological Treatment
🇺🇸
Nashville, Tennessee, United States
Diagnostic Health
🇺🇸
Nashville, Tennessee, United States
Salt Lake Regional Medical Center (X-rays only)
🇺🇸
Salt Lake City, Utah, United States
Salt Lake Research, PLLC
🇺🇸
Salt Lake City, Utah, United States
Spitalul Clinic Prof. Dr. Th. Burghele
🇷🇴
Bucuresti, Romania
Martinska fakultna nemocnica
🇸🇰
Martin, Slovakia
Szpital Kliniczny Dzieciatka Jezus, Centrum Leczenia Obrazen
🇵🇱
Warszawa, Poland
MILAB s.r.o.
🇸🇰
Presov, Slovakia
Taipei Veterans General Hospital/Department of Surgery
🇨🇳
Taipei, Taiwan
Urology of Rosmedtechnology
🇷🇺
Moscow, Russian Federation
Coastal Clinical Research, Inc.
🇺🇸
Mobile, Alabama, United States
Canyon State Urology
🇺🇸
Glendale, Arizona, United States
Arizona Research Center
🇺🇸
Phoenix, Arizona, United States
Scottsdale Medical Imaging
🇺🇸
Scottsdale, Arizona, United States
Radiology Limited (x-ray only)
🇺🇸
Tucson, Arizona, United States
Arizona Urologic Specialists
🇺🇸
Tucson, Arizona, United States
Urology Associates of Central California
🇺🇸
Fresno, California, United States
Access Medical Imaging
🇺🇸
Beverly Hills, California, United States
Citrus Valley Medical Research Inc.
🇺🇸
Glendora, California, United States
Institute for Advanced Urology
🇺🇸
Los Angeles, California, United States
Tri Valley Urology Group
🇺🇸
Murrieta, California, United States
Boulder Medical Center, PC
🇺🇸
Boulder, Colorado, United States
Valley Neurology
🇺🇸
Murrieta, California, United States
Liberty Pacific Medical Imaging
🇺🇸
Signal Hill, California, United States
Longmont Clinic, PC
🇺🇸
Longmont, Colorado, United States
Grove Hill Clinical Research
🇺🇸
New Britain, Connecticut, United States
Diagnostic Imaging (radiology only)
🇺🇸
Dover, Delaware, United States
Urology Center of Grove Hill
🇺🇸
New Britain, Connecticut, United States
Urology Associates of Dover
🇺🇸
Dover, Delaware, United States
Brian J. Hines, MD
🇺🇸
Stamford, Connecticut, United States
Stamford Therapeutics Consortium
🇺🇸
Stamford, Connecticut, United States
Visions Clinical Research
🇺🇸
Boynton Beach, Florida, United States
Jacksonville Center for Clinical Research
🇺🇸
Jacksonville, Florida, United States
Specialists in Urology
🇺🇸
Naples, Florida, United States
University Urologists
🇺🇸
Lake Worth, Florida, United States
Advanced Urology Associates
🇺🇸
New Port Richey, Florida, United States
Renstar Medical Research
🇺🇸
Ocala, Florida, United States
Ocala Urology Specialists
🇺🇸
Ocala, Florida, United States
Urology Specialists of West Florida
🇺🇸
New Port Richey, Florida, United States
Advanced Imaging Center Incorporated
🇺🇸
Ocala, Florida, United States
Excel Medical Imaging
🇺🇸
New Port Richey, Florida, United States
Pinellas Urology, Inc.
🇺🇸
Saint Petersburg, Florida, United States
Gateway Radiology (x-rays only)
🇺🇸
Pinellas Park, Florida, United States
Atlanta Medical Research Institute, LLC
🇺🇸
Alpharetta, Georgia, United States
Advanced Research Institute Incorporated
🇺🇸
Trinity, Florida, United States
Northside Hospital Radiology Services (x-ray only)
🇺🇸
Alpharetta, Georgia, United States
Atlanta Center for Medical Research
🇺🇸
Atlanta, Georgia, United States
MRI Imaging of Georgia
🇺🇸
Atlanta, Georgia, United States
MRI Imaging Of Georgia
🇺🇸
Atlanta, Georgia, United States
Deaconess Clinic Downtown Research Institute
🇺🇸
Evansville, Indiana, United States
Deaconess Clinic Gateway Health Center Research Institute
🇺🇸
Newburgh, Indiana, United States
Georgia Urology
🇺🇸
Decatur, Georgia, United States
Metropolitan Urology
🇺🇸
Jeffersonville, Indiana, United States
The Iowa Clinic, Medical Imaging
🇺🇸
West Des Moines, Iowa, United States
Urology of Indiana, LLC
🇺🇸
Noblesville, Indiana, United States
American Health Network (X-Ray only)
🇺🇸
Noblesville, Indiana, United States
The Iowa Clinic, Urology
🇺🇸
West Des Moines, Iowa, United States
Anne Arundel Urology, PA
🇺🇸
Annapolis, Maryland, United States
Regional Urology, LLC
🇺🇸
Shreveport, Louisiana, United States
Anne Arundel Diagnostics Imaging
🇺🇸
Annapolis, Maryland, United States
Grand Rapids Women's Health dba Female Pelvic Medicine and Urogynecology Institute of Michigan
🇺🇸
Grand Rapids, Michigan, United States
Rheumatology PC
🇺🇸
Kalamazoo, Michigan, United States
Michigan Institute of Urology, P.C.
🇺🇸
Troy, Michigan, United States
Women's Clinic of Lincoln, P.C.
🇺🇸
Lincoln, Nebraska, United States
Southeast Urology Network
🇺🇸
Memphis, Tennessee, United States
CRL Imaging Southdale (x-rays only)
🇺🇸
Edina, Minnesota, United States
Medical Advanced Pain Specialists Applied Research Center Incorporated
🇺🇸
Edina, Minnesota, United States
Benedictine Hospital
🇺🇸
Kingston, New York, United States
Hudson Valley Urology, PC
🇺🇸
Poughkeepsie, New York, United States
Family Health Care Center (X-Ray)
🇺🇸
Lincoln, Nebraska, United States
Capital Region Urological Surgeons
🇺🇸
Albany, New York, United States
University of Rochester Medical Center
🇺🇸
Rochester, New York, United States
University of Rochester, Department of Urology
🇺🇸
Rochester, New York, United States
University Urology Associates
🇺🇸
New York, New York, United States
Salisbury Urological Clinic
🇺🇸
Salisbury, North Carolina, United States
Crescent Medical Research
🇺🇸
Salisbury, North Carolina, United States
DRA Imaging, PC (X-Rays Only)
🇺🇸
Poughkeepsie, New York, United States
Piedmont Medical Research
🇺🇸
Winston-Salem, North Carolina, United States
Central Ohio Urology Group
🇺🇸
Cofumbus, Ohio, United States
Premier Urology
🇺🇸
Westerville, Ohio, United States
Institute for Female Pelvic Medicine and Reconstructive Surgery
🇺🇸
Allentown, Pennsylvania, United States
The Urology Group
🇺🇸
Greer, South Carolina, United States
Urologic Consultants of Southeastern Pennsylvania
🇺🇸
Bala-Cynwyd, Pennsylvania, United States
Jeanes Hospital
🇺🇸
Philadelphia, Pennsylvania, United States
Matrix Research, LLC
🇺🇸
Greer, South Carolina, United States
Bristol Urological Associates, PC
🇺🇸
Bristol, Tennessee, United States
The Neurology Clinic
🇺🇸
Memphis, Tennessee, United States
The West Clinic
🇺🇸
Memphis, Tennessee, United States
Advances In Health, Inc.
🇺🇸
Houston, Texas, United States
Rocky Mountain Neurological Associates
🇺🇸
Murray, Utah, United States
St. Luke's Diagnostic and Treatment Center Kirby Glen
🇺🇸
Houston, Texas, United States
Salt Lake Surgical Center
🇺🇸
Murray, Utah, United States
Western Urological Clinic, PC
🇺🇸
Salt Lake City, Utah, United States
Integrity Medical Research, LLC
🇺🇸
Mountlake Terrace, Washington, United States
Urology Northwest
🇺🇸
Mountlake Terrace, Washington, United States
Universitair Ziekenhuis Brussel
🇧🇪
Brussel, Belgium
Universitair Ziekenhuis Gent
🇧🇪
Gent, Belgium
Universitair Ziekenhuis Gasthuisberg
🇧🇪
Leuven, Belgium
The Gateway 2
🇨🇦
Abbotsford, British Columbia, Canada
The Male/Female Health and Research Centre, Royal Court Medical Centre
🇨🇦
Barrie, Ontario, Canada
Kingston General Hospital
🇨🇦
Kingston, Ontario, Canada
Centre for Applied Urological Research
🇨🇦
Kingston, Ontario, Canada
Sunnybrook Health Sciences Centre
🇨🇦
Toronto, Ontario, Canada
Kouvolan Laakariasema
🇫🇮
Kouvola, Finland
Centre Hospitalier Universitaire de Sherbrooke
🇨🇦
Sherbrooke, Quebec, Canada
Harasanshin Hospital, Urology
🇯🇵
Fukuoka-shi, Fukuoka, Japan
Kyoto City Hospital, Urology
🇯🇵
Nakagyo-ku, Kyoto-shi, Kyoto, Japan
Tokyo Women's Medical University Medical Center East
🇯🇵
Arakawa-ku, Tokyo, Japan
Tokyo University Hospital
🇯🇵
Bunkyo-ku, Tokyo, Japan
Department of Urology, Asan Medical Center, University of Ulsan
🇰🇷
Songpa-gu, Seoul, Korea, Republic of
SPZOZ Wojewodzki Szpital Zespolony im. Jedrzeja Sniadeckiego, Oddzial Urologii
🇵🇱
Bialystok, Poland
Department of Urology, Korea University Anam Hospital
🇰🇷
Seoul, Korea, Republic of
Spoldzielnia Pracy Specjalistow Radiologow
🇵🇱
Warszawa, Poland
Conti Medica Sp. z o.o.
🇵🇱
Warszawa, Poland
Dinu Uromedica SCM
🇷🇴
Bucuresti, Sector 4, Romania
NZOZ Centrum Medyczne Wola
🇵🇱
Warszawa, Poland
Centrul Medical Sf. Pantelimon
🇷🇴
Pantelimon, Romania
Federal State Institution Scientific Research Institute of Urology of Rosmedtechnology
🇷🇺
Moscow, Russian Federation
Saint-Petersburg State Healthcare Institution City Hospital # 15/Department of Urology
🇷🇺
Saint-Petersburg, Russian Federation
SEIHPE St. Petersburg State Medical University n.a.I.P. Pavlov Roszdrava
🇷🇺
St. Petersburg, Russian Federation
SEIHPE St. Petersburg State Medical University n.a.I.P. Pavlov Roszdrava/Chair of Urology
🇷🇺
St. Petersburg, Russian Federation
Univerzitna nemocnica Martin
🇸🇰
Martin, Slovakia
Clinica Del Remei - Instituto Medico Tecnologico
🇪🇸
Barcelona, Spain
Hospital Universitario Puerta de Hierro Majadahonda
🇪🇸
Majadahonda, Madrid, Spain
Medicinsk Rontgen (x-ray only)
🇸🇪
Malmo, Sweden
Hospital Clinic I Provincial de Barcelona
🇪🇸
Barcelona, Spain
Kliniska provningsenheten
🇸🇪
Goteborg, Sweden
Chang Gung Medical Foundation - Kaohsiung/Department of Surgery
🇨🇳
Koahsiung Hsien, Taiwan
Center for Lakemedelsprovning Malmo
🇸🇪
Malmo, Sweden
Taichung Hospital, Department of Health, Executive Yuan
🇨🇳
Taichung City, Taiwan
Taipei Veterans General Hospital (X-Ray Only)
🇨🇳
Taipei, Taiwan
Beaumont Hospitals - Royal Oak
🇺🇸
Royal Oak, Michigan, United States
Alabama Orthopaedic Clinic
🇺🇸
Mobile, Alabama, United States
HealthCare Midwest
🇺🇸
Kalamazoo, Michigan, United States
Beyer Research
🇺🇸
Kalamazoo, Michigan, United States
Midtown Imaging
🇺🇸
West Palm Beach, Florida, United States
Department of Urology, Seoul National University Hospital
🇰🇷
Seoul, Korea, Republic of
Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine
🇰🇷
Seoul, Korea, Republic of
Longmont Medical Research Network
🇺🇸
Longmont, Colorado, United States
Women's Health Specialty Care
🇺🇸
Farmington, Connecticut, United States
Genesis Clinical Research and Consulting
🇺🇸
Fall River, Massachusetts, United States
Atlantic Urology Medical Group
🇺🇸
Long Beach, California, United States
Planned Parenthood of Arkansas and Eastern Oklahoma
🇺🇸
Tulsa, Oklahoma, United States
Oklahoma State University
🇺🇸
Tulsa, Oklahoma, United States
Volunteer Research Group
🇺🇸
Knoxville, Tennessee, United States
New Orleans Center for Clinical Research
🇺🇸
Knoxville, Tennessee, United States
University Urology
🇺🇸
Knoxville, Tennessee, United States
Department of Obstetrics & Gynaecology, Prince of Wales Hospital The Chinese University of Hong Kong
🇭🇰
Shatin, NEW Territories, Hong Kong
Department of Surgery, The Chinese University of Hong Kong
🇭🇰
Shatin, Hong Kong